Multiple Institutions Give AIM a “Buy” Rating HONG KONG SAR – Media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus)...
HONG KONG SAR – Media OutReach Newswire – 20 December 2024 – AIM Vaccine (06660.HK) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval...
An iterative process is highly effective in increasing the value of large items HONG KONG SAR – Media OutReach Newswire – 8 November 2024 – AIM Vaccine (06660.HK), the world’s second largest supplier of rabies vaccines, announced on 7th November...
Application for drug marketing registration duly submitted Super heavyweight items are expected to drive performance soaring HONG KONG SAR – Media OutReach Newswire – 1 November 2024 – AIM Vaccine (06660.HK) announced on 1st November that the application for drug...
It is expected to become the world’s first heavyweight iteration of a major item to be launched on the market HONG KONG SAR – Media OutReach Newswire – 7 October 2024 – AIM Vaccine announced on the evening of October...
HONG KONG SAR – Media OutReach Newswire – 2 October 2024 – The Hong Kong stock market’s pharmaceutical sector has seen a strong rebound recently. Among them, AIM Vaccine Co., Ltd. (06660.HK) led the rise in the biopharmaceutical sector. Its...
